NephroDI Therapeutics is developing an oral therapy targeting Nephrogenic Diabetes Insipidus (NDI) in children, a condition that causes excessive urine production due to the kidneys' inability to concentrate urine. The company's novel AMPK-targeted approach aims to reduce the daily fluid intake required to prevent severe dehydration and associated health complications.
Funding
$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Nephrogenic Diabetes Insipidus (NDI) in children is a rare genetic condition where the kidneys cannot concentrate urine, leading to excessive urine production (up to 20 liters per day). This inability to concentrate urine forces children to drink large amounts of water to avoid severe dehydration, which can lead to mental retardation and progressive kidney damage.
Solution
NephroDI Therapeutics is developing a first-in-class oral therapy that targets the underlying mechanisms of NDI. Their novel AMPK-targeted approach aims to improve the kidney's ability to concentrate urine, thereby reducing the amount of fluid intake required to prevent dehydration and associated health complications. This treatment seeks to address the unmet need for a convenient and effective therapy that can improve the quality of life for children with NDI.
Target Audience
The primary target audience is children suffering from Congenital Nephrogenic Diabetes Insipidus (NDI) and their families.
Features
- Oral drug formulation for convenient administration.
- Targets AMPK to enhance kidney function in concentrating urine.
- Designed to reduce excessive urine production associated with NDI.